<?xml version="1.0" ?>
<!DOCTYPE PubmedArticleSet PUBLIC "-//NLM//DTD PubMedArticle, 1st January 2023//EN" "https://dtd.nlm.nih.gov/ncbi/pubmed/out/pubmed_230101.dtd">
<PubmedArticleSet>
<PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM" IndexingMethod="Automated"><PMID Version="1">35098554</PMID><DateCompleted><Year>2022</Year><Month>06</Month><Day>15</Day></DateCompleted><DateRevised><Year>2022</Year><Month>07</Month><Day>31</Day></DateRevised><Article PubModel="Print-Electronic"><Journal><ISSN IssnType="Electronic">1097-4598</ISSN><JournalIssue CitedMedium="Internet"><Volume>66</Volume><Issue>1</Issue><PubDate><Year>2022</Year><Month>Jul</Month></PubDate></JournalIssue><Title>Muscle &amp; nerve</Title><ISOAbbreviation>Muscle Nerve</ISOAbbreviation></Journal><ArticleTitle>Phase 2B randomized controlled trial of NP001 in amyotrophic lateral sclerosis: Pre-specified and post hoc analyses.</ArticleTitle><Pagination><StartPage>39</StartPage><EndPage>49</EndPage><MedlinePgn>39-49</MedlinePgn></Pagination><ELocationID EIdType="doi" ValidYN="Y">10.1002/mus.27511</ELocationID><Abstract><AbstractText Label="INTRODUCTION/AIMS">ALS is a heterogeneous disease that may be complicated or in part driven by inflammation. NP001, a regulator of macrophage activation, was associated with slowing disease progression in those with higher levels of the plasma inflammatory marker C-reactive protein (CRP) in phase 2A studies in ALS. Here, we evaluate the effects of NP001 in a phase 2B trial, and perform a post hoc analysis with combined data from the preceding phase 2A trial.</AbstractText><AbstractText Label="METHODS">The phase 2B trial enrolled 138 participants within 3&#x2009;y of symptom onset and with plasma hs-CRP values &gt;1.13&#x2009;mg/L. They were randomized 1:1 to receive either placebo or NP001 for 6&#xa0;mo. Change from baseline ALSFRS-R scores was the primary efficacy endpoint. Secondary endpoints included vital capacity (VC) change from baseline and percentage of participants showing no decline of ALSFRS-R score over 6&#xa0;mo (non-progressor).</AbstractText><AbstractText Label="RESULTS">The phase 2B study did not show significant differences between placebo and active treatment with respect to change in ALSFRS-R scores, or VC. The drug was safe and well tolerated. A post hoc analysis identified a 40- to 65-y-old subset in which NP001-treated patients demonstrated slower declines in ALSFRS-R score by 36% and VC loss by 51% compared with placebo. A greater number of non-progressors were NP001-treated compared with placebo (p&#xa0;=&#xa0;.004).</AbstractText><AbstractText Label="DISCUSSION">Although the phase 2B trial failed to meet its primary endpoints, post hoc analyses identified a subgroup whose decline in ALSFRS-R and VC scores were significantly slower than placebo. Further studies will be required to validate these findings.</AbstractText><CopyrightInformation>&#xa9; 2022 The Authors. Muscle &amp; Nerve published by Wiley Periodicals LLC.</CopyrightInformation></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Miller</LastName><ForeName>Robert G</ForeName><Initials>RG</Initials><AffiliationInfo><Affiliation>California Pacific Medical Center, San Francisco, California, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Zhang</LastName><ForeName>Rongzhen</ForeName><Initials>R</Initials><AffiliationInfo><Affiliation>Department of Medicine, University of California San Francisco, San Francisco, California, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Bracci</LastName><ForeName>Paige M</ForeName><Initials>PM</Initials><AffiliationInfo><Affiliation>Department of Epidemiology and Biostatistics, University of California San Francisco, San Francisco, California, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Azhir</LastName><ForeName>Ari</ForeName><Initials>A</Initials><AffiliationInfo><Affiliation>Neuvivo, Inc., Palo Alto, California, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Barohn</LastName><ForeName>Richard</ForeName><Initials>R</Initials><AffiliationInfo><Affiliation>University of Missouri, Columbia, Missouri, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Bedlack</LastName><ForeName>Richard</ForeName><Initials>R</Initials><AffiliationInfo><Affiliation>Duke University Medical Center, Durham, North Carolina, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Benatar</LastName><ForeName>Michael</ForeName><Initials>M</Initials><AffiliationInfo><Affiliation>University of Miami Miller School of Medicine, Miami, Florida, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Berry</LastName><ForeName>James D</ForeName><Initials>JD</Initials><AffiliationInfo><Affiliation>Massachusetts General Hospital, Boston, Massachusetts, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Cudkowicz</LastName><ForeName>Merit</ForeName><Initials>M</Initials><AffiliationInfo><Affiliation>Massachusetts General Hospital, Boston, Massachusetts, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Kasarskis</LastName><ForeName>Edward J</ForeName><Initials>EJ</Initials><AffiliationInfo><Affiliation>University of Kentucky, Lexington, Kentucky, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Mitsumoto</LastName><ForeName>Hiroshi</ForeName><Initials>H</Initials><AffiliationInfo><Affiliation>Columbia University Medical Center, New York, New York, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Manousakis</LastName><ForeName>Georgios</ForeName><Initials>G</Initials><AffiliationInfo><Affiliation>University of Minnesota Medical School, Minneapolis, Minnesota, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Walk</LastName><ForeName>David</ForeName><Initials>D</Initials><AffiliationInfo><Affiliation>University of Minnesota Medical School, Minneapolis, Minnesota, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Oskarsson</LastName><ForeName>Bjorn</ForeName><Initials>B</Initials><AffiliationInfo><Affiliation>Department of Neurology, Mayo Clinic, Florida, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Shefner</LastName><ForeName>Jeremy</ForeName><Initials>J</Initials><AffiliationInfo><Affiliation>Barrow Neurological Institute, University of Arizona College of Medicine Phoenix, Creighton University College of Medicine Phoenix, Phoenix, Arizona, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>McGrath</LastName><ForeName>Michael S</ForeName><Initials>MS</Initials><Identifier Source="ORCID">0000-0002-7232-2602</Identifier><AffiliationInfo><Affiliation>Department of Medicine, University of California San Francisco, San Francisco, California, USA.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Neuvivo, Inc., Palo Alto, California, USA.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D016449">Randomized Controlled Trial</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2022</Year><Month>06</Month><Day>03</Day></ArticleDate></Article><MedlineJournalInfo><Country>United States</Country><MedlineTA>Muscle Nerve</MedlineTA><NlmUniqueID>7803146</NlmUniqueID><ISSNLinking>0148-639X</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D015415">Biomarkers</NameOfSubstance></Chemical><Chemical><RegistryNumber>9007-41-4</RegistryNumber><NameOfSubstance UI="D002097">C-Reactive Protein</NameOfSubstance></Chemical></ChemicalList><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D000690" MajorTopicYN="Y">Amyotrophic Lateral Sclerosis</DescriptorName><QualifierName UI="Q000175" MajorTopicYN="N">diagnosis</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D015415" MajorTopicYN="N">Biomarkers</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D002097" MajorTopicYN="N">C-Reactive Protein</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D018450" MajorTopicYN="N">Disease Progression</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D004311" MajorTopicYN="N">Double-Blind Method</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D014797" MajorTopicYN="N">Vital Capacity</DescriptorName><QualifierName UI="Q000502" MajorTopicYN="N">physiology</QualifierName></MeshHeading></MeshHeadingList><KeywordList Owner="NOTNLM"><Keyword MajorTopicYN="N">C-reactive protein (CRP)</Keyword><Keyword MajorTopicYN="N">NP001</Keyword><Keyword MajorTopicYN="N">amyotrophic lateral sclerosis (ALS)</Keyword><Keyword MajorTopicYN="N">inflammation</Keyword><Keyword MajorTopicYN="N">respiratory function</Keyword></KeywordList><CoiStatement>R.G. Miller, the author reports no conflict of interest. R. Zhang, the author reports no conflict of interest. P.M. Bracci, the author reports no conflict of interest. A. Azhir, CEO of Neuvivo Inc. R. Barohn has received research grants from NIH and consulting support from NuFactor. R. Bedlack has received research support from ALSA, Healey Center, MediciNova. He has received consulting support from AB Science, ALSA, Alexion, Amylyx, Apellis, Biogen, Biohaven, Brainstorm, Clene, Corcept, Cytokinetics, GenieUS, Guidepoint, ITF Pharma, Mallinkrodt, Orphazyme, Shinkei, Woolsey Pharma. M. Benatar, the author reports no conflict of interest. J.D. Berry, the author reports no conflict of interest. M. Cudkowicz, the author reports no conflict of interest. E.J. Kasarskis, the author reports no conflict of interest. H. Mitsumoto has received research funding from NIH, ALS Association, SPF, MDA Wings, Tsumura &amp; Co, Mitsubishi&#x2010;Tanabe Pharma. He has participated in advisory boards for Amylyx, PTC Bio (one time). G. Manousakis, the author reports no conflict of interest, D. Walk, the author reports no conflict of interest. B. Oskarsson the author, reports no conflict of interest. J. Shefner has received grant/research/clinical trial support from Amylyx, Biogen, Cytokinetics Incorporated, Mitsubishi Tanabe Pharma America, Sanofi, Novartis, Annexon, Jannsen. Alexion, Medicinova, Ionis, and Alector. He has received personal compensation from Amylyx, Apic Biosciences, Neurosense, Cytokinetics, Denal, GSK, Mitsubishi Tanabe Pharma America, RRD, Swanbio, Helixsmith, Novartis, Sanofi, and Sawei. M.S. McGrath, Founder and Chief scientific officer of Neuvivo Inc. Did not personally access the Neuvivo database for the primary analysis described in this manuscript.</CoiStatement></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="revised"><Year>2022</Year><Month>1</Month><Day>19</Day></PubMedPubDate><PubMedPubDate PubStatus="received"><Year>2021</Year><Month>11</Month><Day>29</Day></PubMedPubDate><PubMedPubDate PubStatus="accepted"><Year>2022</Year><Month>1</Month><Day>22</Day></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2022</Year><Month>2</Month><Day>1</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2022</Year><Month>6</Month><Day>16</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2022</Year><Month>1</Month><Day>31</Day><Hour>6</Hour><Minute>7</Minute></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">35098554</ArticleId><ArticleId IdType="pmc">PMC9327716</ArticleId><ArticleId IdType="doi">10.1002/mus.27511</ArticleId></ArticleIdList><ReferenceList><Reference><Citation>Kiernan MC, Vucic S, Cheah BC, et al. Amyotrophic lateral sclerosis. Lancet. 2011;377:942&#x2010;955.</Citation><ArticleIdList><ArticleId IdType="pubmed">21296405</ArticleId></ArticleIdList></Reference><Reference><Citation>Abe K, Itoyama Y, Sobue G, et al. Confirmatory double&#x2010;blind, parallel&#x2010;group, placebo&#x2010;controlled study of efficacy and safety of edaravone (MCI&#x2010;186) in amyotrophic lateral sclerosis patients. Amyotroph Lateral Scler Frontotemporal Degener. 2014;15:610&#x2010;617.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4266079</ArticleId><ArticleId IdType="pubmed">25286015</ArticleId></ArticleIdList></Reference><Reference><Citation>Butovsky O, Siddiqui S, Gabriely G, et al. Modulating inflammatory monocytes with a unique microRNA gene signature ameliorates murine ALS. J Clin Invest. 2012;122:3063&#x2010;3087.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3428086</ArticleId><ArticleId IdType="pubmed">22863620</ArticleId></ArticleIdList></Reference><Reference><Citation>Lunetta C, Lizio A, Maestri E, et al. Serum C&#x2010;reactive protein as a prognostic biomarker in amyotrophic lateral sclerosis. JAMA Neurol. 2017;74:660&#x2010;667.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5822215</ArticleId><ArticleId IdType="pubmed">28384752</ArticleId></ArticleIdList></Reference><Reference><Citation>Hooten KG, Beers DR, Zhao W, Appel SH. Protective and toxic Neuroinflammation in amyotrophic lateral sclerosis. Neurotherapeutics. 2015;12:364&#x2010;375.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4404435</ArticleId><ArticleId IdType="pubmed">25567201</ArticleId></ArticleIdList></Reference><Reference><Citation>Yu CH, Davidson S, Harapas CR, et al. TDP&#x2010;43 triggers mitochondrial DNA release via mPTP to activate cGAS/STING in ALS. Cell. 2020;183:636&#x2010;649.e18.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7599077</ArticleId><ArticleId IdType="pubmed">33031745</ArticleId></ArticleIdList></Reference><Reference><Citation>Kallstig E, McCabe BD, Schneider BL. The links between ALS and NF&#x2010;kappaB. Int J Mol Sci. 2021;22(8):3875. 10.3390/ijms22083875</Citation><ArticleIdList><ArticleId IdType="doi">10.3390/ijms22083875</ArticleId><ArticleId IdType="pmc">PMC8070122</ArticleId><ArticleId IdType="pubmed">33918092</ArticleId></ArticleIdList></Reference><Reference><Citation>Natale G, Biagioni F, Busceti CL, Gambardella S, Limanaqi F, Fornai F. TREM receptors connecting bowel inflammation to neurodegenerative disorders. Cells. 2019;8(10):1124. 10.3390/cells8101124</Citation><ArticleIdList><ArticleId IdType="doi">10.3390/cells8101124</ArticleId><ArticleId IdType="pmc">PMC6829526</ArticleId><ArticleId IdType="pubmed">31546668</ArticleId></ArticleIdList></Reference><Reference><Citation>Jin X, Liu MY, Zhang DF, et al. Natural products as a potential modulator of microglial polarization in neurodegenerative diseases. Pharmacol Res. 2019;145:104253.</Citation><ArticleIdList><ArticleId IdType="pubmed">31059788</ArticleId></ArticleIdList></Reference><Reference><Citation>McGill RB, Steyn FJ, Ngo ST, et al. Monocyte CD14 and HLA&#x2010;DR expression increases with disease duration and severity in amyotrophic lateral sclerosis. Amyotroph Lateral Scler Frontotemporal Degener. 2021;1&#x2010;8. 10.1080/21678421.2021.1964531</Citation><ArticleIdList><ArticleId IdType="doi">10.1080/21678421.2021.1964531</ArticleId><ArticleId IdType="pubmed">34396845</ArticleId></ArticleIdList></Reference><Reference><Citation>Zhang R, Gascon R, Miller RG, et al. Evidence for systemic immune system alterations in sporadic amyotrophic lateral sclerosis (sALS). J Neuroimmunol. 2005;159:215&#x2010;224.</Citation><ArticleIdList><ArticleId IdType="pubmed">15652422</ArticleId></ArticleIdList></Reference><Reference><Citation>Giese T, McGrath MS, Stumm S, Schempp H, Elstner E, Meuer SC. Differential effects on innate versus adaptive immune responses by WF10. Cell Immunol. 2004;229:149&#x2010;158.</Citation><ArticleIdList><ArticleId IdType="pubmed">15474529</ArticleId></ArticleIdList></Reference><Reference><Citation>McGrath MS, Kahn JO, Herndier BG. Development of WF10, a novel macrophage&#x2010;regulating agent. Curr Opin Investig Drugs. 2002;3:365&#x2010;373.</Citation><ArticleIdList><ArticleId IdType="pubmed">12054081</ArticleId></ArticleIdList></Reference><Reference><Citation>Schempp H, Reim M, Dornisch K, Elstner EF. Chlorite&#x2010;hemoprotein interaction as key role for the pharmacological activity of the chlorite&#x2010;based drug WF10. Arzneimittelforschung. 2001;51:554&#x2010;562.</Citation><ArticleIdList><ArticleId IdType="pubmed">11505786</ArticleId></ArticleIdList></Reference><Reference><Citation>Joo K, Lee Y, Choi D, et al. An anti&#x2010;inflammatory mechanism of taurine conjugated 5&#x2010;aminosalicylic acid against experimental colitis: taurine chloramine potentiates inhibitory effect of 5&#x2010;aminosalicylic acid on IL&#x2010;1beta&#x2010;mediated NFkappaB activation. Eur J Pharmacol. 2009;618:91&#x2010;97.</Citation><ArticleIdList><ArticleId IdType="pubmed">19616541</ArticleId></ArticleIdList></Reference><Reference><Citation>Miller RG, Zhang R, Block G, et al. NP001 regulation of macrophage activation markers in ALS: a phase I clinical and biomarker study. Amyotroph Lateral Scler Frontotemporal Degener. 2014;15:601&#x2010;609.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5524125</ArticleId><ArticleId IdType="pubmed">25192333</ArticleId></ArticleIdList></Reference><Reference><Citation>Miller RG, Block G, Katz JS, et al. Randomized phase 2 trial of NP001&#x2010;a novel immune regulator: safety and early efficacy in ALS. Neurol Neuroimmunol Neuroinflamm. 2015;2:e100.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4396529</ArticleId><ArticleId IdType="pubmed">25884010</ArticleId></ArticleIdList></Reference><Reference><Citation>Brooks BR, Miller RG, Swash M, Munsat TL. World Federation of Neurology Research Group on motor neuron D. El Escorial revisited: revised criteria for the diagnosis of amyotrophic lateral sclerosis. Amyotroph Lateral Scler Other Motor Neuron Disord. 2000;1(5):293&#x2010;299.</Citation><ArticleIdList><ArticleId IdType="pubmed">11464847</ArticleId></ArticleIdList></Reference><Reference><Citation>Andrews JA, Meng L, Kulke SF, et al. Association between decline in slow vital capacity and respiratory insufficiency, use of assisted ventilation, tracheostomy, or death in patients with amyotrophic lateral sclerosis. JAMA Neurol. 2018;75:58&#x2010;64.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5833488</ArticleId><ArticleId IdType="pubmed">29181534</ArticleId></ArticleIdList></Reference><Reference><Citation>Pinto S, de Carvalho M. SVC is a marker of respiratory decline function, similar to FVC, in patients with ALS. Front Neurol. 2019;10:109.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6403463</ArticleId><ArticleId IdType="pubmed">30873101</ArticleId></ArticleIdList></Reference><Reference><Citation>Ziv&#x2010;Baran T, Shenhar&#x2010;Tsarfaty S, Etz&#x2010;Hadar I, et al. The ability of the wide range CRP assay to classify individuals with low grade inflammation into cardiovascular risk groups. Clin Chim Acta. 2017;471:185&#x2010;190.</Citation><ArticleIdList><ArticleId IdType="pubmed">28606604</ArticleId></ArticleIdList></Reference><Reference><Citation>Beers DR, Zhao W, Neal DW, et al. Elevated acute phase proteins reflect peripheral inflammation and disease severity in patients with amyotrophic lateral sclerosis. Sci Rep. 2020;10:15295.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7499429</ArticleId><ArticleId IdType="pubmed">32943739</ArticleId></ArticleIdList></Reference><Reference><Citation>Cui C, Sun J, Pawitan Y, et al. Creatinine and C&#x2010;reactive protein in amyotrophic lateral sclerosis, multiple sclerosis and Parkinson's disease. Brain Commun. 2020;2:fcaa152.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7850290</ArticleId><ArticleId IdType="pubmed">33543134</ArticleId></ArticleIdList></Reference><Reference><Citation>Huysai K, Gecgel SK. Comparison of high sensitive C&#x2010;reactive protein levels with other biomarkers in cardiovascular disease risk assessment. Int J Clin Exp Med. 2019;12:4339&#x2010;4346.</Citation></Reference><Reference><Citation>Ngwa DN, Agrawal A. Structure&#x2010;function relationships of C&#x2010;reactive protein in bacterial infection. Front Immunol. 2019;10:166.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6400226</ArticleId><ArticleId IdType="pubmed">30863393</ArticleId></ArticleIdList></Reference><Reference><Citation>Goyal NA, Berry JD, Windebank A, et al. Addressing heterogeneity in amyotrophic lateral sclerosis CLINICAL TRIALS. Muscle Nerve. 2020;62:156&#x2010;166.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7496557</ArticleId><ArticleId IdType="pubmed">31899540</ArticleId></ArticleIdList></Reference><Reference><Citation>Bedlack RS, Vaughan T, Wicks P, et al. How common are ALS plateaus and reversals? Neurology. 2016;86:808&#x2010;812.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4793781</ArticleId><ArticleId IdType="pubmed">26658909</ArticleId></ArticleIdList></Reference></ReferenceList></PubmedData></PubmedArticle></PubmedArticleSet>